VMAT2 availability in Parkinson’s disease with probable REM sleep behaviour disorder

Autor: Sang Soo Cho, Antonio P. Strafella, Alexander Mihaescu, Mario Masellis, Carme Uribe, Robert Chen, Mikaeel Valli
Jazyk: angličtina
Rok vydání: 2021
Předmět:
medicine.medical_specialty
Positron emission tomography
Parkinson's disease
Dopamine
Nigrostriatal pathway
Substantia nigra
Neurones
Dopamina
REM Sleep Behavior Disorder
Vesicular monoamine transporter 2
03 medical and health sciences
Cellular and Molecular Neuroscience
VMAT2
0302 clinical medicine
Internal medicine
Malaltia de Parkinson
medicine
Humans
RC346-429
Molecular Biology
030304 developmental biology
Trastorns del son
Denervation
Neurons
0303 health sciences
Dopamine Plasma Membrane Transport Proteins
biology
Putamen
Research
Subthalamus
Parkinson Disease
Sleep disorders
medicine.disease
Corpus Striatum
REM sleep behaviour disorder
[11C]DTBZ
medicine.anatomical_structure
Endocrinology
Globus pallidus
nervous system
Vesicular Monoamine Transport Proteins
biology.protein
Parkinson’s disease
Tomografia per emissió de positrons
Neurology. Diseases of the nervous system
030217 neurology & neurosurgery
Zdroj: Molecular Brain, Vol 14, Iss 1, Pp 1-9 (2021)
Molecular Brain
Dipòsit Digital de la UB
Universidad de Barcelona
ISSN: 1756-6606
Popis: REM sleep behaviour disorder (RBD) can be an early non-motor symptom of Parkinson’s disease (PD) with pathology involving mainly the pontine nuclei. Beyond the brainstem, it is unclear if RBD patients comorbid with PD have more affected striatal dopamine denervation compared to PD patients unaffected by RBD (PD-RBD−). To elucidate this, we evaluated the availability of vesicular monoamine transporter 2 (VMAT2), an index of nigrostriatal dopamine innervation, in 15 PD patients with probable RBD (PD-RBD+), 15 PD-RBD−, and 15 age-matched healthy controls (HC) using [11C]DTBZ PET imaging. This technique measured VMAT2 availability within striatal regions of interest (ROI). A mixed effect model was used to compare the radioligand binding of VMAT2 between the three groups for each striatal ROI, while co-varying for sex, cognitive function and depression scores. Multiple regressions were also computed to predict clinical measures from group condition and VMAT2 binding within all ROIs explored. We observed a significant main effect of group condition on VMAT2 availability within the caudate, putamen, ventral striatum, globus pallidus, substantia nigra, and subthalamus. Specifically, our results revealed that PD-RBD+ had lower VMAT2 availability compared to HC in all these regions except for the subthalamus and substantia nigra, while PD-RBD− was significantly lower than HC in all these regions. PD-RBD− showed a negative relationship between motor severity and VMAT2 availability within the left caudate. Our findings reflect that both PD patient subgroups had similar denervation within the nigrostriatal pathway. There were no significant interactions detected between radioligand binding and clinical scores in PD-RBD+. Taken together, VMAT2 and striatal dopamine denervation in general may not be a significant contributor to the pathophysiology of RBD in PD patients. Future studies are encouraged to explore other underlying neural chemistry mechanisms contributing to RBD in PD patients.
Databáze: OpenAIRE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje